Table 2.
Pharmacokinetic properties of nemonoxacin in 12 healthy Chinese volunteers after a single oral dose of 500 mg of nemonoxacin alone or with cimetidine
| Parameters | Nemonoxacin alone (Treatment C) | Nemonoxacin with cimetidine (Treatment D) | Geometric mean ratio (D:C)a |
|---|---|---|---|
| AUC0−t, h·μg/mL | 50.8 (8.9) | 55.3 (9.6) | 1.08 (1.04–1.13) |
| AUC0−∞, h·μg/mL | 51.2 (9.0) | 56.0 (9.8) | 1.09 (1.04–1.14) |
| Cmax, μg/mL | 7.20 (1.12) | 6.90 (1.26) | 0.95 (0.86–1.04) |
| tmax, h | 1 (1–1.5)b | 1.5 (0.67–2.5)b | – |
| t1/2, h | 13.7 (0.8) | 13.8 (1.9) | – |
| MRT, h | 9.74 (1.29) | 11.5 (1.6) | – |
| CL/F, L/h | 10.0 (1.6) | 9.21 (1.73) | – |
| Vz/F, L | 199 (37) | 183 (40) | – |
| Fe, % | 62.5 (7.9) | 59.2 (9.9) | 0.94 (0.87–1.02) |
| CLr, L/h | 6.32 (1.33) | 5.48 (1.24) | 0.87 (0.78–0.96) |
Notes: Data are mean (standard deviation), except
point estimates (90% confidence intervals) and
medians (ranges). The dash indicates no data available.
Abbreviations: AUC0−∞, area under the plasma concentration–time curve from time 0 to infinity; AUC0−t, area under the plasma concentration time curve from time 0 to the last time point; Cmax, maximum concentration; CL/F, oral clearance; CLr, renal clearance; Fe, percentage of the administered dose recovered in the urine; MRT, mean residence time; t1/2, terminal elimination half-life; tmax, time to reach Cmax; Vz/F, terminal volume of distribution without correction for bioavailability.